The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease

Psychopharmacology

Volumn 132, Issue 3, 1997, Pages 217-226

  Van Dyck, Christopher H ^a   Lin, C Huie ^a   Robinson, Rhonda ^a   Cellar, Janet ^a   Smith, Eileen O ^a   Nelson, J Craig ^a   Arnsten, Amy F T ^a   Hoffer, Paul B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

99mTc ECD; Alzheimer's disease; Linopirdine; SPECT

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CYSTEINE ETHYL ESTER TC 99M; LINOPIRDINE; PLACEBO;

ACETYLCHOLINE RELEASE; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASSOCIATION CORTEX; BEHAVIOR; BRAIN BLOOD FLOW; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARIETAL LOBE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARIETAL LOBE; PYRIDINES; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030744573     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050339     Document Type: Article

References (59)

1. Alavi A, Newberg AB, Souder E, Berlin JA (1993) Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 34:1681-1687
2. Alberici GP, Cook L, Gaskill J-L, Steinfels GF (1991) The electroencephalographic (EEG) effects of DuP 996, a compound with cognitive enhancing properties. Soc Neurosci Abstr 17:1588
3. 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of 1-acetylcarnitine. Eur Neurol 29:261-265
4. Baumgarten M, Becker R. Gauthier S (1990) The validity and reliability of the Dementia Behavior Disturbance Scale. J Am Geriatr Soc 38:221-226
5. Besson JAO, Crawford JR, Evans NTS, Gemmell HG, Roeda D (1992) PET imaging in Alzheimer's disease. J R Soc Med 85:231-234
6. Bonte FJ, Devous MDS, Reisch JS (1988) The effect of acetazolamide on regional cerebral blood flow in normal human subjects as measured by single-photon emission tomography. Invest Radiol 23:564-568
7. Bonte FJ, Devous MDS, Reisch JS, Ajmani AK, Weiner MF, Hom J. Tintner R (1989) The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. Invest Radiol 24:99-103
8. Clarke T, Bryce DK, Rollema H (1995) Effects of the release enhancer DuP 996 on the in vivo release of DA and 5-HT in rat striatum. Soc Neurosci Abstr 21:1977
9. Cook L, Nickolson VJ, Steinfels GF, Rohrbach KW, De-Noble VJ (1990) Cognition enhancement by the acetylcholine releaser DuP 996. Drug Dev Res 19:301-314
10. DeNoble VJ, DeNoble KF, Spencer KR, Johnson LC, Cook L, Myers MJ, Seribner RM (1990) Comparison of Dup 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. Pharmacol Biochem Behav 36:957-961
11. Dent GW, Rule BL, Tam SW, De Souza EB (1993) Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats. Brain Res 620:7-15
12. Devons MDS, Payne JK, Lowe JK, Leroy RF (1993) Comparison of technetium-99m-ECD to xenon-133 SPECT in normal controls and in patients with mild to moderate regional cerebral blood flow abnormalities. J Nucl Med 34:754-761
13. ® kit for the preparation of technelium Tc99m bicisate injection. The Du Pont Merck Pharmaceutical Company, Billerica, Massachusetts
14. Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, Patterson J, Hanson MT, Siegfried K, Goodwin GM (1992) Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 108:103-109
15. Estrada C, Hamel E, Krause DN (1983) Biochemical evidence for cholinergic innervation of intracerebral blood vessels. Brain Res 266:261-270
16. Folstein MF, Fostein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
17. Frackowiak RSJ, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, Jones T (1981) Regional cerebral oxygen supply and utilization in dementia. Brain 104: 753-778
18. Geaney DP, Soper N, Shepstone BJ, Cowen PJ (1990) Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet 335:1484-1487
19. Genna S, Smith AP (1988) The development of ASPECT, an annular single crystal brain camera for high efficiency SPECT. IEEE Trans Nucl Sci NS-35:654-658
20. Gustafson I, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosén I, Fernö H (1987) Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 93:31-35
21. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Ross Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632-637
22. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
23. Holman BL, Carvalho PA, Zimmerman RE, Johnson KA, Tumch SS, Smith AP, Genua S (1990) Brain perfusion SPECT using an annular single crystal camera: initial clinical experience. J Nucl Med 31:1456-1461
24. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A (1992) The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 33:181-185
25. Hunter R, Wyper DJ, Patterson J, Hansen MT, Goodwin GM (1991) Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography. Br J Psychiatry 158:351-357
26. Johnson KA, Holman BL, Rosen TJ, Nagel JS, English RJ, Growdon JH (1990) Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. Arch Intern Med 150:752-756
27. Johnson KA, Sperling RA, Becker JA, Satlin A, Renshaw P, Holman BL (1994) Atrophy-corrected SPECT cerebral perfusion in Alzheimer's disease. J Nucl Med 35:20P
28. Kievit J, Kuypers HGJM (1975) Basal forebrain and hypothalamic connections to frontal and parietal cortex in the rhesus monkey. Science 187:660-662
29. Kumar A, Schapiro MB, Grady C, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI (1991) High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 4:35-46
30. Kushner M, Tobin M, Alavi A, Chawluk J, Rosen M, Fazekas F, Alavi J, Reivich M (1987) Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. J Nucl Med 28:1667-1670
31. Lévcillé J, Demonceau G, De Roo M, Rigo P, Taillefer R, Morgan RA, Kupranick D, Walovitch RC (1989) Characterization of technetium-99m-L, L-ECD for brain perfusion imaging, part 2: biodistribution and brain imaging in humans. J Nucl Med 30:1902-1910
32. + ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cerebral cortical slices. J Pharmacol Exp Ther 271:891-897
33. Marynowski M, Maciag C, Rominger CM, Rominger D, Tam SW, Zaczek R (1993) Effects of linopirdine (DuP 996) on hippocampal extracellular levels of acetylcholine in freely movine animals. Soc Neurosci Abstr 19:1040
34. Matsui T, Hirano A (1978) An atlas of the human brain for computerized tomography. Igaku-Shoin, Tokyo
35. Mattis S (1976) Mental status examination for organic mental syndrome in the elderly patient. In: Bellack L, Karasu TB (eds) Geriatric psychiatry. Grune & Stratton, New York, pp 77-121
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939-944
37. Meltzer CC, Zuhieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ (1996) Regional hypometabolisin in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 47:454-461
38. Mesulam M-M, Mufson EJ, Levey AI, Wainer BH (1983) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantial innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170-197
39. Minthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, Rosén I, Seiving B, Wendt PE (1993) Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 4:32-42
40. Muramoto O, Sugishita M, Sugita H, Toyokura Y (1979) Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol 36:501-503
41. Muramoto O, Sugishita M, Ando K (1984) Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 47:485-491
42. Najlerahim A, Bowen DM (1988) Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism. Biochem J 251:305-308
43. Nickolson VJ, Tam SW, Myers MJ, Cook L (1990) Dup 996 (3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Dev Res 19:285-300
44. NIMH (1985) CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:839-844
45. 99mTc] ethyl cysteinate dimer in nonhuman primates. Stroke 21:1059-1063
46. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, Najlerahim A, Patel AJ, Hunt A, Bowen DM (1988) Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 84:125-140
47. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356-1364
48. Saletu B, Darragh A, Salmon P, Coen R (1989) EEG brain mapping in evaluating the time-course of the central action of DUP 996 a new acetylcholine releasing drug. Br J Clin Pharmacol 28:1-16
49. Smith TM, Ramirez AD, Heck SD, Jasys VJ, Volkmann RA, Forman JT, Liston DR (1993) In vivo microdialysis and pharmacokinetic studies with DuP-996. Soc Neurosci Abstr 19:1041
50. Szelies B, Herholz K, Pawlik G, Beil C, Wienhard K, Heiss W-D (1986) Zerebraler glukosestoffwechsel bei präseniler demenz vom Alzheimer-typ-verlaufskontrolle unter therapie mit muskarinergem cholinagonisten. Fortschr Neurol Psychiat 54:364-373
51. Tam SW, Rominger D, Nickolson VJ (1991) Novel Receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and seorotonin release. Mol Pharmacol 40:16-21
52. Tomlinson BE, Corsellis JAN (1984) Aging and the dementias. In: Adams HJ, Corsellis JAN, Duchen LW (eds) Greenfield's neuropathology. Wiley, New York, pp 951-1025
53. Tsuchida T, Yonekura Y, Sadato N, Iwasaki Y, Tamaki N, Konishi J, Fujita T, Matoba N, Nishizawa S, Magata Y (1992) Brain perfusion SPECT with [Tc-99m)-L,L-ethyl cysteinate dimer (ECD) in comparison with regional cerebral blood flow measured by PET: underestimation in the high flow range. J Nucl Med 33:966-967
54. Tsuchida T, Nishizawa S, Yonekura Y, Sadata N, Iwasaki Y, Fujita T, Matoba N, Magata Y, Tamaki N, Konishi J (1994) SPECT Images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET. J Nucl Med 35:27-31
55. Tune L, Brandt J, Frost JJ, Harris G, Mayberg H, Steele C, Burns A, Sapp J, Folstein MF, Wagner HN, Pearlson GD (1991) Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand Suppl 366:61-65
56. Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, Tikofsky RS, Stabin MG, Morgan RA, Goldsmith SJ (1989) Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 30:599-604
57. Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JT, Price DL (1994) Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14: 167-186
58. Walovitch RC, Hill TC, Garrity ST, Cheesman EH, Burgess BA, O'Leary DH, Watson AD, Ganey MV, Morgan RA, Williams SJ (1989) Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, part 1: pharmacology of technetium-99m ECD in nonhuman primates. J Nucl Med 30:1892-1901
59. Wechsler D (1981) Wechsler adult intelligence scale revised. Psychological Corporation, New York